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New Role for
he Natriuretic Peptides
etabolic Regulators of the Adipocyte*
isa C. Costello-Boerrigter, MD, PHD,
ohn C. Burnett, JR, MD
ochester, Minnesota
he heart and adipose tissue are both endocrine organs, and
here is increasing evidence for cross talk between them,
lthough precise mechanisms remain poorly defined. Of
articular importance is the role that such cross talk could
lay in both total body metabolism and cardiac metabolism.
he timely and thought-provoking article by Tsukamoto
t al. (1) in this issue of the Journal adds to this body of
nowledge by examining both in vitro and in vivo the
iological actions of cardiac natriuretic peptides on adi-
onectin production and secretion.
See page 2070
By now the cardiovascular community is well aware that
trial natriuretic peptide (ANP) and brain natriuretic pep-
ide (BNP) promote vasodilation and natriuresis, improve
iastolic function, suppress aldosterone, and inhibit cardiac
ypertrophy and fibrosis (2,3). Less well known is that ANP
nd BNP have metabolic roles; specifically, ANP and BNP
re lipolytic and slow gastric emptying and absorption (4,5).
ndeed, the binding of ANP or BNP to the natriuretic
eptide receptor-A (NPR-A) receptor, which is present in
dipocytes, results in the production of the second messen-
er cGMP. The cGMP in turn activates protein kinase G,
eading to phosphorylation of hormone sensitive lipase
HSL). The HSL is thus activated, and hydrolysis of fatty
cids ultimately occurs (4,6). In addition, ANP has been
hown to induce postprandial lipid oxidation in humans (7).
hese lipolytic actions of ANP and BNP, which generally
re assumed to be primate-specific, underscore an emerging
ole for the heart in human metabolism (8).
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Cardiorenal Research Laboratory, Mayo Clinic and Foundation, Roch-
ster, Minnesota. Supported by National Institutes of Health grants HL36634 and
L76611. The Mayo Clinic and Foundation has licensed novel natriuretic peptidesa
o Nile Therapeutics and Anexon. Dr. Burnett has received a grant from Scios, and
s chair of the Nile Scientific Advisory Board.This role has caused speculation as to the potential role of
hronic, pathological BNP elevation in cardiac cachexia (9).
onversely, plasma BNP and N-terminal pro–B-type na-
riuretic peptide (NT-proBNP) levels are depressed in obese
atients as compared with lean patients, despite the obese
atients having greater left ventricular end-diastolic pres-
ures. This finding has led to the conjecture that de-
reased natriuretic peptide concentrations in the obese
re secondary to a relatively decreased myocardial syn-
hesis or impaired release from the cardiomyocytes (10).
ndeed, this suppression of ANP and BNP in obese
atients could, based upon the cardiorenal and metabolic
roperties of ANP and BNP, contribute to clinical
henotypes associated with the metabolic syndrome.
urthermore, the newly appreciated metabolic properties
f these 2 cardiac hormones may suggest a novel thera-
eutic target in metabolic diseases such as obesity.
Adiponectin, a 244-amino acid peptide that is known to
elf-associate to form multimers, was first described in 1995
nd is also emerging as an important regulator of metabo-
ism (11–14). Adiponectin is primarily, if not exclusively,
hought to be produced by adipocytes, although the authors
f some studies have shown that cardiomyocytes produce
ow levels of adiponectin and that there is a significant
tep-up of adiponectin levels in the coronary sinus compared
ith the aortic root in heart failure (HF) patients, suggest-
ng that there may be cardiac release of adiponectin in
atients with HF (15,16). Despite the fact that adiponectin
s primarily produced by adipose tissue, there seems to be
n almost-paradoxical relationship between adiponectin
lasma concentrations and body mass index. Indeed, it is
ell established that, in humans, plasma adiponectin levels
re inversely related to body mass index and percent body fat
17). Plasma adiponectin concentrations are low in the
bese, in patients with diabetes and in those with insulin
esistance, and in patients with coronary atherosclerotic
isease (18–20). In contrast, plasma adiponectin levels are
igh in individuals with anorexia nervosa and in HF
atients with cachexia (21–23). Furthermore, the adminis-
ration of exogenous adiponectin to animals resulted in
eight loss (24).
The authors of previous studies have found a positive
orrelation between adiponectin and NT-proBNP or BNP
evels in HF patients and in normal individuals (23,25,26).
eight loss after bariatric surgery has been shown to result
n increased adiponectin as well as BNP and NT-proBNP
evels (27,28). It has also been shown in a small clinical
tudy that decompensated HF patients who received ANP
nfusions had increased plasma levels of total and high
olecular weight (multimeric) adiponectin (29).
With all of this background, the work of Tsukamoto et al.
1) adds mechanistic insights. Importantly, the authors
emonstrated that ANP and BNP via the cGMP pathway
ncrease adiponectin messenger ribonucleic acid expression
nd increase adiponectin secretion from cultured adipocytes.
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June 2, 2009:2078–9 Metabolic Regulators of the Adipocyteow this functionally impacts HF is still unclear, although
hese authors and others have speculated that, in the setting
f HF, adiponectin secretion may occur to attenuate the
hronic energy deprivation the heart faces as it switches
rom predominantly fatty acid oxidation to glucose oxida-
ion (1,15,23). Also, the natriuretic peptide-induced lipol-
sis and adiponectin secretion could aid in weight loss,
hich in the setting of HF could be considered a cardiac
nloading action. An extreme form of this could be cardiac
achexia. Clearly, there is a need for further work in this
ascinating area.
eprint requests and correspondence: Dr. Lisa C. Costello-
oerrigter, Cardiorenal Research Laboratory, Mayo Clinic and
oundation, 200 First Street SW, Rochester, Minnesota 55905.
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